• Increase font size
  • Default font size
  • Decrease font size
Message
  • Please Login First
  • Please Login First

Stem cells show extraordinary potential to treat various cancers

Print E-mail
By Staff and Wire Reports   
Wednesday, 10 March 2010 11:22

Could latest results mean that IMUC is close to securing a partnership? ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) announced today that its dendritic cell-based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.


CEO, Dr. Manish Singh told BioMedReports: “We believe this data, while received from animal studies, provides compelling evidence that cancer stem cells have extraordinary potential to treat various cancers. There were many promising markers,  including increased Gamma-Interferon levels in animals treated with CSCs, which suggest an increased immune response which is consistent with increased survival outcomes. We are excited about moving this into the clinic, as other companies have entered into partnerships with major pharmaceutical companies on less compelling data from animal studies."

According to the company, rats were either immunized with cancer stem cells (CSCs) from a brain cancer tumor or the daughter cells (the bulk of the tumor), and results showed that  that those immunized with the CSCs had a median survival of 50 days compared to 29 days for daughter cells. Furthermore, 30% of animals vaccinated against cancer stem cells demonstrated long term survival as compared to animals vaccinated with the bulk of the tumor, all of which died.

“We are excited by the study’s results, as it represents a significant step forward in the continued development of our cancer stem cell based vaccines,” said Dr. Manish Singh , PhD., President and CEO of ImmunoCellular Therapeutics.  “The data further validates our research indicating that targeting CSCs has the potential to be a highly effective method of treating various cancers.”  The data also demonstrated increased Gamma-Interferon levels in animals treated with CSCs, indicating an increased immune response consistent with increase in survival further supporting the mechanism of action of this approach.

 




BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 15 hours ago FDA panel votes against Xgeva; Nervous GlaxoSmithKline Pulls Cash Out of Eurozone: Below is a look at some of th... http://t.co/h6kQSAz6
about 1 day ago Illumina’s Board Unanimously Rejects Roche’s Offer; Shire Announces FDA Approval of Vyvanse®: Below is a look at... http://t.co/L3FZivQV
about 2 days ago Achillion ($ACHN) hammered after BofA rates to "Underperform" citing no M&A speculation. What we said last month: http://t.co/usWk95O6
about 2 days ago Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 2 days ago Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 2 days ago Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 2 days ago $CVM up 17% and technically looks like it may head higher.
about 3 days ago $ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr

navigation

Free Phone Trade Alerts